Brokerages Set Enovis Corporation (NYSE:ENOV) Target Price at $47.43

Shares of Enovis Corporation (NYSE:ENOV) have earned an average rating of “Buy” from the nine ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $47.4286.

Several equities research analysts have issued reports on ENOV shares. Wall Street Zen downgraded Enovis from a “buy” rating to a “hold” rating in a report on Sunday. Needham & Company LLC lifted their price objective on Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Evercore reiterated an “outperform” rating on shares of Enovis in a research report on Monday, January 12th. BTIG Research increased their target price on Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Finally, UBS Group restated a “buy” rating and set a $50.00 target price on shares of Enovis in a report on Monday, January 5th.

Insider Buying and Selling at Enovis

In other Enovis news, insider Oliver Engert purchased 1,000 shares of the business’s stock in a transaction on Friday, February 27th. The shares were purchased at an average cost of $25.50 per share, with a total value of $25,500.00. Following the transaction, the insider directly owned 43,640 shares of the company’s stock, valued at $1,112,820. This represents a 2.35% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders have purchased 5,000 shares of company stock worth $121,983. 2.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Enovis

Hedge funds and other institutional investors have recently bought and sold shares of the business. River Road Asset Management LLC grew its stake in Enovis by 3.2% in the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after buying an additional 46,289 shares during the last quarter. Corient Private Wealth LLC raised its holdings in Enovis by 540.7% in the 4th quarter. Corient Private Wealth LLC now owns 55,180 shares of the company’s stock valued at $1,470,000 after acquiring an additional 46,568 shares during the period. Front Street Capital Management Inc. lifted its position in Enovis by 75.8% during the fourth quarter. Front Street Capital Management Inc. now owns 361,932 shares of the company’s stock worth $9,642,000 after acquiring an additional 156,069 shares during the last quarter. XTX Topco Ltd acquired a new stake in Enovis during the fourth quarter worth approximately $561,000. Finally, Susquehanna Portfolio Strategies LLC boosted its holdings in shares of Enovis by 249.9% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 140,997 shares of the company’s stock worth $3,756,000 after acquiring an additional 100,704 shares during the period. Institutional investors own 98.45% of the company’s stock.

Enovis Price Performance

ENOV opened at $22.43 on Friday. The company has a fifty day moving average price of $23.17 and a two-hundred day moving average price of $27.43. The firm has a market capitalization of $1.28 billion, a PE ratio of -1.08 and a beta of 1.46. Enovis has a 52 week low of $21.00 and a 52 week high of $40.69. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.81 by $0.14. The company had revenue of $575.76 million for the quarter, compared to the consensus estimate of $584.30 million. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts anticipate that Enovis will post 2.79 earnings per share for the current year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.